Hofseth BioCare ASA: NEW PEER-REVIEWED CLINICAL STUDY ON PROGO® PUBLISHED IN BIOMEDICINES DEMONSTRATES GLP-1 BENEFITS AND AN INCREASE LEAN MUSCLE MASS

Hofseth  BioCare ASA  ("HBC") announces  the publication  of a new peer-reviewed
clinical  study on  its salmon  protein hydrolysate  ProGo® in the international
scientific journal Biomedicines. The randomised, double-blind, active-controlled
pilot  study  reports  that  56 days  of  daily  ProGo® supplementation improved
multiple  biological markers relevant to healthy  ageing and metabolic health in
overweight adults, while a protein-matched whey comparator did not.

In  the study,  14 overweight adults  received either  12 g/day of ProGo® or 12
g/day  of an  iso-nitrogenous whey  protein isolate  over 56 days.  Because both
products  were matched  for protein  content and  dose, the differences observed
between the groups are attributed to the bioactivity of ProGo®'s peptides rather
than  to protein  intake alone.  The trial  is registered  on clinicaltrials.gov
(NCT07616752).

Whilst  this was a pilot study of  14 people ProGo®'s impact was large enough to
reveal   consistent,  statistically  significant  signals  across  a  number  of
independent   measures.   Importantly,  the  results  were  driven  by  all  the
participants, not by a few hyper-responders. Further, whilst there were slightly
more  women  in  the  ProGo®  group  baseline characteristics were well balanced
between  the groups and actually the ProGo® group started with a higher ferritin
level providing a higher bar for greater increases which ProGo® demonstrated.

Across  the pre-specified primary  endpoints, and after  adjustment for multiple
testing,  ProGo® produced statistically significant  improvements versus whey in
haemoglobin  (+3.8%), red blood cell count (+7.5%), mean corpuscular haemoglobin
(+5.7%)  and ferritin (+13.4%), together with a 39.1% improvement in a composite
self-assessed  hair,  nail  and  skin  score. ProGo® contains negligible dietary
iron;  prior research attributes the  iron-related effects to bioactive peptides
that upregulate the iron-storage gene FTH1.

Secondary,  exploratory  analyses,  reported  without  correction  for  multiple
testing  and therefore considered  hypothesis-generating, favoured ProGo® across
body composition, inflammation and glucose metabolism. These included reductions
in  waist circumference (?7.7%),  BMI (?7%) and  percent body fat (?10.7%), with
preservation   of   lean   body  mass  (+13.3%),  alongside  reductions  in  the
inflammatory  markers IL-6, IL-8, IL-12B and TNF-? and improvements in HbA1c and
fasting blood glucose. The whey comparator had minimal impact on these measures.
As a small (n=14) pilot study the findings are preliminary, and the authors note
that larger, longer and placebo-controlled studies are warranted.

ProGo®  Bioactive  Peptides  is  positioned  primarily  in  the  healthy  ageing
category,  having been named winner  in the Healthy Aging  category at the 2025
NutraIngredients-USA Awards and recognised for its metabolic health credentials.
Alongside  the Biomedicines publication, HBC is releasing a white paper, "ProGo®
-  the  Science  of  Healthy  Ageing  &  Metabolic Health", which summarises the
clinical findings for a general audience.

"This  study is  a thought-provoking  first step,  showing that a single, simple
daily supplement can move several of the biological drivers of healthy ageing at
once  - iron metabolism, inflammation, glucose control and body composition - in
a  way a protein-matched comparator did not. We look forward to confirming these
signals  in larger and longer studies" says Dr. Crawford Currie, Head of Medical
R&D at Hofseth BioCare ASA.

For further information, please contact:
Dr Crawford Currie, Head of Medical R&D at Hofseth BioCare ASA
Phone: +44 7968 195497
E-mail: cc@hofsethbiocare.no

About Hofseth BioCare ASA:
Hofseth  BioCare is a Norwegian  consumer and pet health  company founded on the
core values of sustainability, optimal utilization of natural resources and full
traceability.  It upcycles the side streams of the salmon industry, taking fresh
filleted  salmon  and  converting  it  from  a waste product into ingredients to
improve  human and pet health. These ingredients  are ProGo®, a mix of bioactive
peptides  and collagen; OmeGo®, a whole salmon oil containing all the fatty acid
fractions found in fish; and CalGo®/NT-II® salmon bone powder containing calcium
hydroxyapatite  and undenatured collagen  for bone and  joint health. HBC places
scientific  evidence  at  the  forefront,  which  has  led to important academic
partnerships and the identification of unique health benefits.
 forefront\,  which  has  led to important academic\
partnerships and the identification of unique health benefits.\